Parkman Healthcare Partners LLC Purchases 73,205 Shares of LivaNova PLC (NASDAQ:LIVN)

Parkman Healthcare Partners LLC raised its stake in shares of LivaNova PLC (NASDAQ:LIVN) by 72.0% during the fourth quarter, HoldingsChannel reports. The firm owned 174,934 shares of the company’s stock after buying an additional 73,205 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in LivaNova were worth $8,101,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of LIVN. Freestone Grove Partners LP acquired a new position in shares of LivaNova during the fourth quarter valued at about $23,102,000. Artisan Partners Limited Partnership acquired a new position in LivaNova in the fourth quarter valued at about $21,340,000. The Manufacturers Life Insurance Company grew its holdings in shares of LivaNova by 163.6% in the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company’s stock valued at $25,303,000 after purchasing an additional 339,139 shares in the last quarter. AQR Capital Management LLC grew its holdings in LivaNova by 79.3% during the 4th quarter. AQR Capital Management LLC now owns 742,180 shares of the company’s stock worth $34,214,000 after acquiring an additional 328,313 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after acquiring an additional 265,291 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 8th. The Goldman Sachs Group decreased their price objective on shares of LivaNova from $64.00 to $55.00 and set a “buy” rating for the company in a report on Monday, March 3rd. Stifel Nicolaus dropped their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Finally, Robert W. Baird raised their price target on shares of LivaNova from $55.00 to $61.00 and gave the stock an “outperform” rating in a report on Thursday, May 8th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LivaNova currently has a consensus rating of “Moderate Buy” and an average price target of $59.17.

LivaNova Price Performance

Shares of NASDAQ:LIVN opened at $44.06 on Wednesday. LivaNova PLC has a twelve month low of $32.48 and a twelve month high of $63.57. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.40 billion, a PE ratio of 104.90 and a beta of 0.84. The company has a 50-day moving average price of $38.06 and a two-hundred day moving average price of $45.03.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.